Metraipolis › archive › dc_2de7b97abe7f

The Efficacy and Safety of Adding Teniposide to Temozolomide Plus Bevacizumab in Recurrent Grade 4 Glioma: A Real-World Exploratory Single-Center Study — Europe PMC PMID:42941343

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42941343
DOI
10.3390/jcm15207827
License (as archived)
solo-consultazione
Archived
2026-10-31T19:53:07.820Z
SHA-256 of the archived text
a14796c6a8ee0695e69aac3c4761d815cbe61a8ca5b6a464b6ab3b8c13fa8658
Stable URL of this page
https://metraipolis.com/documento/dc_2de7b97abe7f

How to cite

The Efficacy and Safety of Adding Teniposide to Temozolomide Plus Bevacizumab in Recurrent Grade 4 Glioma: A Real-World Exploratory Single-Center Study — Europe PMC PMID:42941343 — Europe PMC (en), https://europepmc.org/article/MED/42941343 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2de7b97abe7f (Metraipolis archive dc_2de7b97abe7f, sha256 a14796c6a8ee0695e69aac3c4761d815cbe61a8ca5b6a464b6ab3b8c13fa8658)
BibTeX
@misc{dc2de7b97abe7f,
  title = {The Efficacy and Safety of Adding Teniposide to Temozolomide Plus Bevacizumab in Recurrent Grade 4 Glioma: A Real-World Exploratory Single-Center Study — Europe PMC PMID:42941343},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42941343},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2de7b97abe7f; sha256 a14796c6a8ee0695e69aac3c4761d815cbe61a8ca5b6a464b6ab3b8c13fa8658},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42941343. Agents can read the archived copy with the MCP tool read_document.